Non-Steroidal Nasal Sprays with no adverse effects for Treatment of Respiratory Diseases, COVID-19, Long COVID, Flu, and more.

Emphycorp News and Peer Reviewed Articles

To read and or download the pdf articles click on the links below.

• European Journal of Respiratory Medicine Peer Review Phase III Results – “The Effect of Sodium Pyruvate Nasal Spray on Coughing in Patients with IPF Coughing” 081324

• EmphyCorp European Journal of Respiratory Medicine Peer Review “Inhaled Sodium Pyruvate Reduces Lung Inflammation and Fibrosis in a Bleomycin Rat Model” 1/9/2024.

• JAMAPDD Published Peer Review “Sodium Pyruvate Nasal Spray Reduces the Severity of Nasal Inflammation and Congestion in Patients with Allergic Rhinitis Sept 2022.
  

  ---

• EJRM Peer Review – Inhaled Sodium Pyruvate Reduces Oxygen Radicals and Inflammatory Cytokines in COPD Patients 073022

• EJRM Peer Review – Inhalation of Sodium Pyruvate to Reduce Hypoxemia and Dyspnea Associated with Chronic Respiratory Diseases- A Multi-Study Retrospective Analysis 011922
  

  ---

• Inhalation of Sodium Pyruvate to Reduce the Symptoms and Severity of Respiratory Diseases Including COVID-19, Long COVID, and Pulmonary Fibrosis.
  

  ---

• October 11, 2021 – N115 Nasal Spray Found to Improve Lung Function in PF Patients
  

  ---

• July 2020 – Inhaled Nebulized Sodium Pyruvate for COVID-19 – Israel Medical Association Journal
  

  ---

• May 2020 – Pyruvate affects inflammatory responses of macrophages during influenza A virus infection – Elsevier Virus Research EmphyCorp p 7-8 highlighted